Материалы научно-практической конференции с международным участием «Перспективы диагностики и лечения гематологических заболеваний» before, during and after photopheresis but their further comparison, through a cuvette with theconcentrate of leucocytes simultaneously with an ultravioletirradiation carried out the test radiation of visible range,determination of dose and adjusting of his intensity. <...> Non- invasive determination of dose of ultraviolet irradiation of concentrate of leucocytes at photpheresis comes true placing of cuvette the concentrate of leucocytes fl owsthrough that, between a test emitter and ofoptical-electronic device and simultaneously exposed to rays by the ultraviolet of area of А. <...> The worked out method allows to conduct non-invasive determination of dose of ultraviolet irradiation of concentrate of leucocytes by means of optical-electronic device on the basis of measuring of changes of optical descriptions of concentrate of leucocytes in a visible area. <...> A method is unconnected with violation of impermeability to the contour at realization of photopheresis and allows considerably to extend possibilities of application of him and get greater informationfor the acceptance of decision a doctor in relation to the correction of the modes of irradiation and expediency of continuation of curative sessions. <...> In addition the method of non invasive determination of dose of ultraviolet irradiation of concentrate of leucocytes allows safely toestimate effi ciency of session of photopheresis on optical descriptions of concentrate of leucocytes during hisrealization and promotes effi ciency and quality of procedure the same and abbreviates common time of treatment. <...> Институт патологии крови и трансфузионной медицины НАМН Украины, Львов, Украина Kotlyarchuk K., Danysh O., Lukavetskyy L., Tsyapka O., Мaslyak Z. Institute of Blood Pathology and Transfusion Medicine of NAMS of Ukraine, Lviv, Ukraine Сосудистый эндотелиальный фактор роста в сыворотке пациентов с ХМЛ в процессе лечения иматинибом Serum levels of vascular endothelial growth factor in CML patients treated with imatinib Актуальность. <...> Изменение генома гемопоэтических клеток при хроническом миелолейкозе (ХМЛ), как и при других неоплазиях, патогенетически связано с неоангиогенезом. <...> Установить значение сосудистого эндотелиального фактора роста (VEGF) для оценки течения и прогнозирования ответа на иматиниб (ИМ) у пациентов с ХМЛ. <...> Изучение уровня VEGF проведено у 40 пациентов в хронической фазе ХМЛ до назначения ИМ, а также на разных <...>